A clever new tuberculosis vaccine has shown promise in trials in mice. If it succeeds, it will be the first new TB vaccine in a century.
With the rise of multidrug resistant tuberculosis, the difficulty of curing the disease, and the large annual death toll, a successful vaccine could be a huge benefit to public health—especially in low- and middle income countries. The research is published January 13th in Applied and Environmental Microbiology, a journal of the American Society for Microbiology.
The vaccine uses “biobeads” as a platform to present the antigens from the tuberculosis bacterium to the immune system. These biobeads are natural polyesters that certain non-tuberculosis bacteria assemble into tiny spheres. Researchers have engineered them to display antigens from tuberculosis bacteria, Mycobacterium tuberculosis or Mycobacterium bovis. (image: mycobacterium tuberculosis Ziehl-Neelsen stain credit: CDC)
In earlier research, these investigators found that mycobacterial antigens displayed on the biobeads could induce cell-mediated immune responses in mice. Those biobeads were assembled by E.coli. “During these experiments the team observed that along with the tuberculosis antigens, E. coli proteins were attached to the surfaces of the crude biobeads,” said principal investigator Axel Heiser, PhD, Senior Scientist, AgResearch Ltd., Palmerston North, New Zealand.
“From these observations, we developed the hypothesis that these proteins could also function as antigens,” said Heiser. “If produced in Mycobacteria instead of E. coli, such biobeads should carry mycobacterial antigens on their surface, including many as yet undiscovered antigens which would have the potential to induce protective immunity.” And that, in addition to antigens from M. tuberculosis and M. bovis that they would deliberately engineer onto the biobeads, would boost immune response to the vaccine, he said.
But unlike E. coli, Mycobacteria lack the enzymes necessary to assemble biobeads, said Heiser. So they developed new cloning strategies that enabled expression of those enzymes in M. smegmatis, a mycobacterium that does not cause tuberculosis. Using M. smegmatis instead of tuberculosis-causing bacteria would avoid the possibility of the vaccine’s causing tuberculosis infection.
Following production of the biobeads, “We killed and broke up the bacteria, and purified the biobeads,” said Heiser. “They are completely natural, and have been shown to be biodegradable.”
“We then used these mycobacterial biobeads to vaccinate mice and tested the mice for immune responses,” said Heiser. “We saw evidence of cell-mediated immunity with the potential to be protective against TB. Future studies will include a vaccination followed by challenge with TB to show protection, and also the development of more efficient production and purification methods for the vaccine.”
Thus, said Heiser, mycobacterial biobeads would provide a new platform for combining a large antigenic repertoire, comparable to that of live vaccines, with high safety through the use of non-infectious material in the vaccine, including absence of any genetic material. Heiser also said that production would be cost-efficient.
In 2015, 10.4 million people contracted tuberculosis, and 1.8 million died, worldwide, according to the World Health Organization. Nearly half a million of the new cases were multidrug-resistant. 95 percent of the deaths occur in middle- and low-income countries. TB is a leading killer of people with HIV. The only existing vaccine was first used in 1921, and has a variety of shortcomings, including that it can cause the disease in immunocompromised people.
Receive an email update when we add a new TUBERCULOSIS article.
The Latest on: Multidrug resistant tuberculosis
via Google News
The Latest on: Multidrug resistant tuberculosis
- Toward more effective TB patient care on April 8, 2019 at 8:17 pm
People have to realize that anyone can contract TB or MDR-TB (multidrug-resistant tuberculosis). In places where there is a high prevalence of TB, like the Philippines, the chances of becoming ... […]
- Whole genome sequencing identifies bacterial factors affecting transmission of multidrug-resistant tuberculosis in a high-prevalence setting on April 3, 2019 at 2:04 am
Whole genome sequencing (WGS) can elucidate Mycobacterium tuberculosis (Mtb) transmission patterns but more data is needed to guide its use in high-burden settings. In a household-based TB ... […]
- A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis on April 1, 2019 at 8:28 am
Cohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health ... […]
- Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China on March 28, 2019 at 4:28 pm
Purpose: Cycloserine has been used in multidrug-resistant tuberculosis (MDR-TB) treatment since the 1950s. We evaluated the efficacy and safety of cycloserine and sought to clarify the role of ... […]
- Qatar to mark World Tuberculosis Day on March 23, 2019 at 1:50 am
The emergence of multidrug-resistant tuberculosis poses a major threat to global health security and may jeopardize gains in tuberculosis control. Qatar Philharmonic Orchestra is all set for tonight’s ... […]
- Qatar marks World Tuberculosis Day on March 22, 2019 at 12:37 pm
The emergence of multidrug-resistant tuberculosis poses a major threat to global health security and may jeopardize gains in tuberculosis control. […]
- 'Short' drug-resistant TB regimen could cut treatment time by more than half on March 13, 2019 at 7:10 pm
A new drug cocktail reduces the length of treatment for multidrug-resistant tuberculosis from nearly two years to nine to 11 months with a similar effectiveness, according to a large clinical trial ... […]
- Study proposes new approach that cures multidrug-resistant TB in conflict-affected communities on February 13, 2019 at 9:39 pm
A high proportion of multidrug-resistant tuberculosis (TB) cases can be cured in conflict-affected communities with molecular diagnostics, shorter treatment periods and socioeconomic incentives, ... […]
- Outbreak of multidrug-resistant tuberculosis undetected by standard tests on October 19, 2018 at 9:22 am
Amid a plan announced by the United Nations to eradicate tuberculosis by 2030, a new study has revealed the emergence of multidrug-resistant strains of the disease which go undetected by WHO-endorsed ... […]
via Bing News